Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian CancerMansoor R. Mirza, Ursula A. Matulonis, Bradley J. Monk et al.|New England Journal of Medicine|2016Cited by 2.5k
Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trialKathleen N. Moore, Bradley J. Monk, Angeles Alvarez Secord et al.|The Lancet Oncology|2019Cited by 533
A single-cell landscape of high-grade serous ovarian cancerBenjamin Izar, Aviv Regev, Itay Tirosh et al.|Nature Medicine|2020Cited by 522
Institutional implementation of clinical tumor profiling on an unselected cancer populationLynette M. Sholl, Laura E. MacConaill, Vanessa Tassell et al.|JCI Insight|2016Cited by 447
Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancerAnniina Färkkilä, Panagiotis A. Konstantinopoulos, D. Gulhan et al.|Nature Communications|2020Cited by 342